secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001628280-23-028183
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo Q2 net loss $114.5M, revenue down 77% YoY; impairments of $51.3M
------------------------------------------------------------------------

- Net loss $114.5M ($0.66/sh) vs $43.2M ($0.29/sh) YoY, driven by $51.3M intangible asset impairment.
- Revenue $6.8M vs $29.4M YoY, down 77% due to terminations of Novartis, Biogen, Sanofi deals.
- Total GAAP op expenses $130.4M (incl. $51.3M impairment); non-GAAP op expenses $72.3M.
- Cash & marketable securities $182.1M at June 30; raised $15.1M via ATM; cash runway >12 months.
- Updated 2023 GAAP op expense guidance $378-398M; non-GAAP unchanged at $240-260M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828023028183/0001628280-23-028183-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828023028183/sgmo-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-028183

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer